(DOC) Healthpeak Properties, Inc. Company Overview

What does Healthpeak Properties do?

Healthpeak Properties, Inc. is a healthcare real estate investment trust listed on the New York Stock Exchange under DOC. The company describes itself as an owner, operator, and developer of healthcare real estate focused on “Discovery and Outpatient Care,” which is useful shorthand for two asset categories: lab campuses serving life science tenants and outpatient medical buildings serving health systems, physicians, and patients. Healthpeak’s own strategy page says it was founded in 1985, has approximately 700 properties nationwide, and concentrates on markets where scale, relationships, and long-term healthcare demand can create an advantage.

What portfolio is Healthpeak trying to own?

The portfolio is built around healthcare delivery and healthcare discovery. Outpatient medical buildings are typically located on or near strong hospital campuses and house physician practices, surgery, imaging, oncology, specialty care, and other services that have migrated away from inpatient hospitals. Lab properties are concentrated in innovation clusters such as San Francisco, Boston, and San Diego, where biopharma tenants need specialized space, scientific talent, and proximity to research ecosystems. The company’s portfolio page shows the operating footprint across outpatient medical and lab assets in multiple U.S. markets.

How does Healthpeak make money?

Healthpeak makes money primarily by owning real estate and collecting rental income, resident fees, and related property income. In REIT analysis, the most important operating measures are not only GAAP net income, which is affected by depreciation and gains on sales, but also net operating income, funds from operations, adjusted funds from operations, occupancy, releasing spreads, leverage, and dividend coverage. For Healthpeak, the business model is asset-heavy and capital-market-sensitive: the company must acquire, develop, lease, finance, recycle, and occasionally sell properties at attractive spreads over its cost of capital.

Which revenue streams matter most?

The annual income statement shows that rent is still the core revenue stream. In FY2025, rental and related revenues were $2.157B, resident fees and services were $604.0M, and interest income and other was $61.8M, for total revenue of $2.823B. Those figures come from the FY2025 reporting package and the company’s fourth-quarter and full-year 2025 results.

How does the property-level cash engine work?

Which segments drive Healthpeak’s economics?

For a healthcare REIT, “segment mix” is best read through same-store cash NOI and leasing performance rather than revenue alone. In Q1 2026, Healthpeak reported total same-store cash adjusted NOI growth of 0.0%. That flat aggregate concealed three different stories: outpatient medical remained positive at +2.4%, lab was under pressure at -7.2%, and senior housing grew +13.8%. The mix of same-store NOI was 55.7% outpatient medical, 33.6% lab, and 10.7% senior housing.

Why does this mix matter?

Outpatient medical gives Healthpeak a stability anchor. Health systems and specialist physicians value proximity to hospital campuses and patient traffic, which supports leasing and retention. Lab offers higher strategic value in clusters such as South San Francisco, Boston, and San Diego, but it is more exposed to biotechnology funding cycles and new supply. Senior housing, increasingly expressed through Janus Living, gives Healthpeak exposure to demographic demand and operating upside but also raises complexity because it depends on operators, labor costs, occupancy, and resident economics.

What strategic turning points shaped Healthpeak today?

Healthpeak is not a static REIT. The current DOC story reflects several repositioning decisions: moving toward healthcare discovery and delivery, emphasizing outpatient medical scale after the Physicians Realty Trust merger, recycling stabilized assets, and separating senior housing visibility through Janus Living.

1. 1985
   Company founded; the original healthcare property focus created the REIT identity that still frames the portfolio.
2. 2019
   Rebranded as Healthpeak Properties; the company sharpened its identity around healthcare real estate.
3. 2022
   Scott M. Brinker became CEO, bringing an investment and healthcare real estate background to portfolio reshaping.
4. 2024
   The Physicians Realty Trust merger expanded outpatient medical scale and changed the ticker to DOC.
5. 2025
   Healthpeak acquired Gateway Crossing in South San Francisco for a total of $600M, deepening its lab footprint.
6. 2026
   Janus Living completed its IPO, with Healthpeak retaining 81.6% ownership and using the structure to make senior housing more visible.

Why is Janus Living a strategic signal?

Janus is important because it changes how investors can evaluate Healthpeak’s senior housing exposure. In Q1 2026, the Janus IPO generated approximately $880M of net proceeds, Healthpeak contributed $714M of senior housing acquisitions as part of the formation transactions, and Healthpeak reported ownership of 81.6% of Janus as of May 4, 2026. The company’s first-quarter 2026 earnings release framed Janus as both a growth platform and a way to participate in senior housing supply-demand fundamentals without burying that business inside the consolidated Healthpeak mix.

What does Healthpeak’s latest quarter show?

The latest official period is the quarter ended March 31, 2026. Healthpeak’s Q1 2026 Form 10-Q reported total revenue of $753.0M, up from $702.9M in Q1 2025, with net income applicable to common shares of $193.5M, or $0.28 per diluted share. The increase in GAAP net income was influenced by gains and other income, so researchers should also watch FFO as adjusted, which was $316.9M, or $0.45 per share.

What changed versus the prior year?

How financially strong is Healthpeak?

Healthpeak’s financial strength depends on leverage, liquidity, access to debt markets, and the spread between property yields and financing costs. The company emphasizes a low cost of capital and an investment-grade balance sheet, including BBB+/Baa1 ratings in its own strategy materials. As of March 31, 2026, the balance sheet showed $21.616B of total assets, $16.837B of net real estate, $1.171B of cash and cash equivalents, $12.556B of total liabilities, and $7.826B of stockholders’ equity.

What balance-sheet lines should analysts watch?

What gives Healthpeak a competitive advantage?

Healthpeak’s moat is narrower than a software network effect but meaningful in real estate terms. It comes from location, specialized property expertise, health-system relationships, clustered lab scale, leasing data, operator relationships, and access to capital. In outpatient medical, many assets sit on leading hospital campuses or close to important care nodes, which can make the building more valuable to physician specialists than a generic office building. In lab, the moat is cluster density: tenants want specialized buildings in markets where talent, capital, universities, and biopharma companies already concentrate.

How does Healthpeak compare with peers?

Competitively, Healthpeak sits between pure healthcare REITs and specialist life science landlords. Welltower and Ventas are larger healthcare REIT peers with major senior housing exposure; Alexandria Real Estate Equities is the best-known pure life science campus peer; and private owners or health systems compete for outpatient medical assets. Healthpeak’s distinction is the combination of outpatient medical scale, lab clusters, and majority exposure to Janus Living after the IPO.

How do capital allocation and the dividend affect the story?

Capital allocation is central because REITs distribute a large portion of taxable income and often depend on external capital for growth. Healthpeak’s 2026 actions show three priorities: unlock senior housing value through Janus, recycle capital from mature assets, and repurchase stock when management believes the share price is attractive relative to asset value.

What should a DCF reader focus on?

For valuation, the critical question is whether capital recycling creates per-share value. A sale of an 80% interest in a 100% occupied six-property outpatient medical portfolio to Blackstone was valued at approximately $212M, or $508 per square foot, with Healthpeak receiving about $170M of gross proceeds while retaining 20% and operating responsibilities. If proceeds are redeployed into higher-yielding acquisitions, developments, or discounted shares, the transaction can support value. If sold assets are replaced with lower-quality growth, it can weaken the thesis.

Who owns Healthpeak stock, and why does governance matter?

Healthpeak has a dispersed public-company ownership profile rather than founder control. The 2026 proxy says the beneficial ownership table is based on information as of March 3, 2026 unless otherwise indicated, and it identifies three greater-than-5% stockholders: Vanguard, BlackRock, and State Street. The same proxy also shows all current directors and executive officers as a group owned less than 1% of the class. That matters because governance influence is more institutional and board-driven than controlled by one founder or family.

What does leadership signal?

Scott M. Brinker has been President and Chief Executive Officer since October 2022, after serving as President and Chief Investment Officer and before that as Executive Vice President and Chief Investment Officer. The 2026 proxy statement emphasizes his investment, underwriting, asset management, capital markets, and healthcare real estate background. For an asset allocator like Healthpeak, that background is directly relevant: management’s job is not just to run properties but to decide which properties should be owned, sold, developed, financed, or contributed to partnerships.

What risks could change Healthpeak’s outlook?

Healthpeak’s risks are not generic “competition and macro” risks. They flow from its business model: specialized real estate, large debt funding needs, tenant and operator credit, interest-rate sensitivity, lab market cycles, senior housing operations, development commitments, and REIT tax rules. The company’s 2025 annual report and 2026 filings include risk-factor language on healthcare property concentration, lab tenant uncertainty, tenant and operator ability to pay, borrowing costs, Janus exposure, REIT qualification, development risk, reimbursement programs, cybersecurity, and legal or environmental liabilities. Researchers can review the company’s 2025 Form 10-K for the full filing context.

Which risks are most material to the model?

Which KPIs matter most for Healthpeak valuation?

A DCF or comparable-company analysis of Healthpeak should not start with generic revenue growth. It should start with property-level cash-flow durability and per-share capital allocation. REIT valuation usually turns on same-store NOI growth, occupancy, leasing spreads, cap rates, cost of debt, FFO per share, AFFO per share, dividend coverage, and development yield versus cost of capital.

What does this mean for a DCF model?

The valuation drivers are straightforward but sensitive. Higher outpatient medical retention and positive releasing spreads support rent growth. Lab recovery could improve occupancy and NOI, but a weak biopharma funding backdrop can lower absorption and increase concessions. Senior housing can lift growth if occupancy and margins improve, but it brings more operating exposure than leased outpatient medical. Cost of capital is the swing factor: a lower debt cost or stronger share price makes acquisitions and development more attractive; a higher debt cost makes asset sales, joint ventures, and buybacks more important.

What is the key takeaway from Healthpeak analysis?

Healthpeak is best understood as a specialized healthcare infrastructure owner trying to balance three economics: the stability of outpatient medical real estate, the cyclical upside and risk of lab campuses, and the demographic growth potential of senior housing through Janus Living. The company matters because it sits at the intersection of care delivery and life science discovery, and because its assets are not interchangeable with ordinary office real estate.

What should researchers watch next?

• Whether FY2026 FFO as adjusted stays within the updated $1.71-$1.75 per share range.
• Whether lab same-store NOI improves from the Q1 2026 7.2% decline.
• Whether outpatient medical releasing spreads remain positive after +5.4% cash spreads on Q1 renewals.
• Whether Janus Living turns senior housing growth into durable cash flow rather than only transaction complexity.
• Whether buybacks, development, acquisitions, and JV recaps improve per-share value after considering leverage.

That is the core research conclusion: Healthpeak is not a simple yield vehicle and not a pure growth REIT. It is a healthcare property allocator whose investment quality depends on segment-level cash flows, balance-sheet discipline, and management’s ability to recycle capital into assets and shares at attractive risk-adjusted returns.